Since 1997, Tianjin Era Biology Technology Co., Ltd. (“Era Biology”) has been dedicated to advancing diagnostic science to address some of healthcare’s most pressing needs. Headquartered in Tianjin, China, Era Biology has grown from a focused project to a global leader in in vitro diagnostics (IVD), particularly in solutions for invasive fungal diseases (IFD).

We have been dedicated to expanding our global influence. Right now, Era Biology has the following 7 wholly-owned subsidiaries:
1. Beijing Gold Mountainriver Tech Development Co., Ltd.
2. Genobio Pharmaceutical Co., Ltd.
3. Beihai Sinlon Co., Ltd.
4. Era Biology (Shanghai) Co., Ltd.
5. Era Biology (Guangzhou) Co., Ltd.
6. Era Biology (Suzhou) Co., Ltd.
Era Biology (Canada) Co., Ltd.

Era Biology is one of the primary entities in drafting and formulating national industry standards. In 2017, Era Biology drafted the industrial standard of Fungus (1-3)-β-D-Glucan Test.

In 2019, Era Biology drafted the industrial standard of the Bacterial Endotoxin Test.

Era Biology is ranked as the #1 domestic fungal detection market share in China. While serving over 1040+ Chinese hospitals, over 80% are tertiary hospitals

While leading the Chinese market, Era Biology has never stopped its footsteps in global expansion. We distributed our devices and reagents in more than 70 countries, and the numbers increase yearly.